Welcome equity investors—today’s edition unlocks Orion AI equity research on five large-cap US Medical Devices stocks: $MDT ( ▼ 1.62% ), $ABT ( ▼ 0.54% ), $BSX ( ▼ 1.4% ), $SYK ( ▼ 1.24% ) and $JNJ ( ▼ 0.33% ).

Scores: Fundamental 7 | Analyst Sentiment 6 | Valuation 5 | Catalyst 8 | Technical 7 | Total: 33

Direction: Neutral to slightly Long

Medtronic presents a compelling tactical long opportunity for the coming week, driven by deeply oversold technical conditions and strong fundamental catalysts. While the stock has experienced a recent pullback, its RSI and Stochastic indicators are in extreme oversold territory, suggesting a high probability of a mean-reversion bounce from the robust support at its 200-day moving average ($89). Fundamentally, $MDT ( ▼ 1.62% ) is poised for future growth with the recent CMS National Coverage Determination for Renal Denervation and the FDA approval and launch of Altaviva for urge urinary incontinence, both opening significant new market opportunities. The planned Diabetes business separation and activist investor involvement further underscore long-term value creation potential. Despite historical underperformance and some analyst skepticism, the confluence of strong technical support, oversold conditions, and developing growth catalysts makes $MDT ( ▼ 1.62% ) attractive for a short-term bounce. A tactical long position with a target at the 50-day MA ($94.20) and a disciplined stop-loss below $88.50 is recommended, acknowledging the moderate confidence due to broader market caution and the need for sustained operational execution.

Read the full report in the attachment, and discover more free reports on our website.

Scores: Fundamental 8 | Analyst Sentiment 9 | Valuation 3 | Catalyst 7 | Technical 5 | Total: 32

Direction: Neutral

Abbott Laboratories presents a compelling long-term investment case, underpinned by its diversified healthcare portfolio, robust innovation engine, and strong financial health. Management's high confidence in future growth, particularly from new product launches in Medical Devices (e.g., Volt PFA, Tendyne) and the tailwinds from GLP-1 drugs benefiting its diabetes and nutrition segments, supports a positive outlook. Analyst sentiment is overwhelmingly bullish, with significant upside potential indicated by price targets. However, for the medium term (1-3 months), a Neutral stance is warranted. The stock's valuation appears stretched relative to peers, and the technical setup indicates neutral to slightly bearish momentum, suggesting a period of consolidation. The most significant near-term risk is the ongoing IRS tax dispute, which could introduce considerable volatility. While $ABT ( ▼ 0.54% )'s defensive characteristics might offer some resilience in a cautious macro environment, the combination of valuation concerns, technical indecision, and the IRS overhang balances the strong fundamental positives. For the coming week, a Neutral trading strategy is recommended, with the stock likely to trade within its recent range ($122-$132). Long-term investors may consider accumulating on dips towards the $122 support, but short-term directional trading is not advised due to the balanced risk-reward profile. Confidence level for this strategy is Medium.

Read the full report in the attachment, and discover more free reports on our website.

Scores: Fundamental 8 | Analyst Sentiment 9 | Valuation 3 | Catalyst 8 | Technical 4 | Total: 32

Direction: Neutral

Boston Scientific presents a compelling long-term growth story driven by strong fundamental performance, innovative product pipeline (WATCHMAN, Farapulse), and a successful strategic acquisition strategy. The company's Q3 2025 results exceeded expectations, management confidence is high, and analyst sentiment is overwhelmingly bullish with significant upside in price targets. However, the stock's current valuation is a major concern, trading at a substantial premium to its peers, which limits immediate upside potential and increases risk. Technically, $BSX ( ▼ 1.4% ) is in a consolidation phase, showing short-term bearish signals (below key moving averages, negative MACD) and underperforming the broader market, which is itself in a short-term pullback. While the long-term trajectory remains positive due to strong catalysts and market leadership, the high valuation combined with recent technical weakness warrants a Neutral stance for the medium term (1-3 months). Investors should await a more attractive entry point, perhaps following a valuation correction or a decisive technical breakout, before initiating or adding to a long position.

Read the full report in the attachment, and discover more free reports on our website.

Scores: Fundamental 8 | Analyst Sentiment 8 | Valuation 3 | Catalyst 7 | Technical 4 | Total: 30

Direction: Neutral

Based on a comprehensive analysis, Stryker is a high-quality medical technology company with strong fundamentals, consistent organic growth, and strategic execution, as evidenced by its recent Q3 earnings beat and raised full-year guidance. Management's confidence in Mako robotics and the Inari Medical integration, despite short-term disruptions, underpins a robust fundamental outlook. Analyst sentiment is overwhelmingly positive, with significant price target upside. However, the stock's valuation is a major concern, trading at a substantial premium to peers across multiple metrics, which is a recurring red flag in research reports. Technically, $SYK ( ▼ 1.24% ) is in a bearish trend, trading below key moving averages and showing negative momentum, although oversold indicators suggest a potential short-term bounce from the lower Bollinger Band support around $350.91. The broader market is in a cautious pullback within an uptrend, which could either provide a defensive haven for quality healthcare stocks or exacerbate selling pressure on overvalued assets. Given the conflicting signals of strong fundamentals/sentiment versus stretched valuation and bearish technicals, a Neutral stance is recommended for the medium term (1-3 months). Investors should monitor for a clearer technical reversal, a more attractive entry point following a deeper correction, or further catalysts that could justify the premium valuation. For short-term traders, a tactical bounce play from the $350.91 support could be considered, but with tight risk management.

Read the full report in the attachment, and discover more free reports on our website.

Scores: Fundamental 7 | Analyst Sentiment 6 | Valuation 4 | Catalyst 5 | Technical 5 | Total: 27

Direction: Neutral

Johnson & Johnson presents a complex investment case, leading to a Neutral stance for the medium term. While the company boasts a strong fundamental core, evidenced by robust Q3 operational performance, a confident management team, and a promising pipeline (e.g., Caplyta expansion, Simponi biosimilar protection), these positives are significantly counterbalanced by emerging and intensifying risks. The most critical is the escalating Tylenol litigation by the Texas AG, which directly challenges J&J's liability shield post-Kenvue spin-off and could lead to substantial financial and reputational damage. Valuation metrics suggest the stock is currently overvalued relative to peers, and its dividend growth rate has slowed, indicating potential growth pressures. Technically, the stock shows mixed signals: while long-term trends are bullish, short-term momentum is weakening, with indicators suggesting consolidation or a pullback from current resistance levels. Given the significant and uncertain legal overhang, coupled with a cautious macro environment and mixed technicals, a wait-and-see approach is prudent. Investors should monitor developments in the Tylenol litigation closely, as its outcome will be a primary driver of $JNJ ( ▼ 0.33% )'s near-term performance. Long-term investors may view any significant dips as potential accumulation opportunities, but short-to-medium term, the risks outweigh clear upside catalysts.

Read the full report in the attachment, and discover more free reports on our website.

Research any US or Hong Kong stock in seconds using Orion AI.

Curious about crypto but still feeling stuck scrolling endless threads? People who get in early aren’t just lucky—they understand the why, when, and how of crypto.

Join our free 3‑day virtual summit and meet the crypto experts who can help you build out your portfolio. You’ll walk away with smart, actionable insights from analysts, developers, and seasoned crypto investors who’ve created fortunes using smart strategies and deep research.

No hype. No FOMO. Just the clear steps you need to move from intrigued to informed about crypto.

Secure your free pass now.

Investors face a dilemma. Headlines everywhere say tariffs and AI hype are distorting public markets.

Now, the S&P is trading at over 30x earnings—a level historically linked to crashes.

And the Fed is lowering rates, potentially adding fuel to the fire.

Bloomberg asked where experts would personally invest $100,000 for their September edition. One surprising answer? Art.

It’s what billionaires like Bezos, Gates, and the Rockefellers have used to diversify for decades.

Why?

Thanks to the world’s premiere art investing platform, now anyone can access works by legends like Banksy, Basquiat, and Picasso—without needing millions. Want in? Shares in new offerings can sell quickly but…

My subscribers skip their waitlist*

_{*Past performance is not indicative of future returns. Important Reg A disclosures: masterworks.com/cd.}

If you want to take advantage of the current bull market but are hesitant about investing, online stock brokers could help take the intimidation out of the process. These platforms offer a simpler, user-friendly way to buy and sell stocks, options and ETFs from the comfort of your home. Check out Money’s list of the Best Online Stock Brokers and start putting your money to work!

Start investing